Monthly Prescribing Reference6d
FDA: Anaphylaxis Risk Prompts Boxed Warning for MS Drug
Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.
Medscape9d
FDA Adds Anaphylaxis Risk Warning to Multiple Sclerosis Drug Glatiramer Acetate
From 1996-2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting ...
GlobalData on MSN8d
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases
The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a ...
The American Journal of Managed Care8d
FDA Warns of Severe Allergic Reactions With Certain Multiple Sclerosis Drugs
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
MedPage Today8d
FDA Warns About Anaphylaxis Risk With MS Drug
The FDA added a boxed warning about rare cases of anaphylaxis associated with the multiple sclerosis (MS) drug glatiramer ...
BioSpace8d
FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
Healio8d
FDA issues anaphylaxis warning on multiple sclerosis treatment
The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...
FDA Warns Of Severe Allergic Reaction Risk With Teva's Multiple Sclerosis Drug
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.